VBL's psoriasis drug candidate meets primary goals in Phase II trial

03/19/2012 | Business Wire

VBL Therapeutics' drug candidate VB-201 significantly reduced vascular inflammation linked to atherosclerotic lesions in patients with severe psoriasis 12 weeks after receiving the treatment, according to a Phase II sub-trial that involved the use of PET/CT scans to assess inflammation. The results were presented at a meeting in San Diego.

View Full Article in:

Business Wire

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR